Bunamiodyl

Summary

Bunamiodyl (CHEMBL2110636) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 639.01 Da · C15H16I3NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110636
Name	Bunamiodyl
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6436657
Molecular formula	C15H16I3NO3
Molecular weight	639.01
InChIKey	CWRBDUIQDIHWJZ-SOFGYWHQSA-N

SMILES: CCCC(=O)NC1=C(C=C(C(=C1I)/C=C(\CC)/C(=O)O)I)I

IUPAC name: (2E)-2-[[3-(butanoylamino)-2,4,6-triiodophenyl]methylidene]butanoic acid

Also known as: Bunamiodilo, Bunamiodyl, BUNAMIODYL

Parent form; salt/anhydrous children: CHEMBL2104558

Patent coverage: 15 distinct patent families (41 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).